Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39. https://doi.org/10.1016/S1470-2045(17)30777-5.

Aquina CT, Ejaz A, Tsung A, Pawlik TM, Cloyd JM. National trends in the use of neoadjuvant therapy before cancer surgery in the US from 2004 to 2016. JAMA Network Open. 2021;4(3):e211031.

Article  PubMed  PubMed Central  Google Scholar 

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. JNCI Monographs. 2001;2001(30):96–102.

Article  Google Scholar 

Volders JH, Negenborn VL, Spronk PE, et al. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):1–12.

Article  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. New Engl J Med. 2021;384(25):2394–405.

Article  CAS  PubMed  Google Scholar 

Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New Engl J Med. 2017;376(22):2147–59.

Article  CAS  PubMed  Google Scholar 

I-SPY2 Trial Consortium. Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6(9):1355–62.

Article  Google Scholar 

Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

Article  PubMed  Google Scholar 

Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. JCO. 1996;14(5):1558–64.

CAS  Google Scholar 

Fisher B, Anderson S, Bryant J, et al. Twenty-Year Follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med. 2002;347(16):1233–41.

Article  PubMed  Google Scholar 

Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr. 1992;11:19–25.

Google Scholar 

Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–85. https://doi.org/10.1200/JCO.1998.16.8.2672. 

Mamounas EP, NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Williston Park). 1997;11(6 Suppl 6):37–40.

CAS  PubMed  Google Scholar 

Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. JCO. 2003;21(22):4165–74.

Article  CAS  Google Scholar 

Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. JCO. 2008;26(5):778–85.

Article  Google Scholar 

Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.

Article  PubMed  PubMed Central  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved.

Veronesi U, Zucali R, Luini A. Local control and survival in early breast cancer: the Milan trial. Int J Radiat Oncol Biol Phys. 1986;12(5):717–20.

Article  CAS  PubMed  Google Scholar 

Sarrazin D, Lê M, Rouëssé J, et al. Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. The experience of the Institut Gustave-Roussy. Cancer. 1984;53(5):1209–13.

Article  CAS  PubMed  Google Scholar 

Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21(12):1602–10.

Article  PubMed  Google Scholar 

Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marks LB, Prosnitz LR. Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves? J Clin Oncol. 2014;32(6):491–3. https://doi.org/10.1200/JCO.2013.51.3523. An excellent commentary offering caution regarding the omission of radiotherapy in a patient cohort that may actually derive the most clinical benefit.

Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology. 2013;14(12):1183–92.

Article  CAS  PubMed  Google Scholar 

Mailhot Vega RB, Wang S, Brooks ED, et al. Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys. 2022;113(3):542–51.

Article  PubMed  Google Scholar 

de Wild SR, de Munck L, Simons JM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23(9):1201–10. Modifying the radiation approach based on risk status after NAC did not worsen clinical outcomes. This serves as justification for a personalized approach to RT in many settings.

Article  PubMed  Google Scholar 

Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013;310(14):1455–61. De-escalating surgery from ALND to SNLB is a major advancement. This study identifies patients that may achieve the benefits of SNLB without losing out on the benefits of ALND.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haffty BG, McCall LM, Ballman KV, et al. Impact of radiation on locoregional control in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: results from ACOSOG Z1071 clinical trial. Int J Radiat Oncol Biol Phys. 2019;105(1):174–82.

Article  PubMed  PubMed Central  Google Scholar 

Kyndi M, Overgaard M, Nielsen HM, et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009;90(1):74–9.

Article  PubMed  Google Scholar 

Stecklein SR, Park M, Liu DD, et al. Long-term impact of regional nodal irradiation in patients with node-positive breast cancer treated with neoadjuvant systemic therapy. Int J Radiat Oncol Biol Phys. 2018;102(3):568–77.

Article  PubMed  Google Scholar 

Mamounas EP, Bandos H, White JR, et al. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). J Clin Oncol. 2019;37(15_suppl):TPS600–TPS600. This trial will give randomized, prospective data regarding axillary nodal irradiation in the setting of cN+, ypN0 disease. The most appropriate radiation strategy is currently unknown.

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01901094, Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. 2013. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT01901094. An ongoing trial examining if ALND can be omitted in favor of radiotherapy in the setting of ypN+ disease.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive her2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

Article  Google Scholar 

Li Y-F, Chang L, Li W-H, et al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: a meta-analysis. The Breast. 2016;27:93–8.

Article  PubMed  Google Scholar 

Corbin KS, Breen WG, Strauss JB. Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1). Clin Transl Radiat Oncol. 2020;24:99–101.

PubMed  PubMed Central  Google Scholar 

Geraud A, Xu HP, Beuzeboc P, Kirova YM. Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. J Neurooncol. 2017;131(1):69–72.

Article  CAS  PubMed  Google Scholar 

Sherry AD, Mayer IA, Ayala-Peacock DN, et al. Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity. Clin Breast Cancer. 2020;20(4):344–352.e1.

Article  CAS  PubMed  Google Scholar 

Woodward WA, Fang P, Arriaga L, et al. A phase 2 study of preoperative capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):777–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4(4):1013–9.

CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. New Engl J Med. 2022;386(6):556–67.

Article  CAS  PubMed  Google Scholar 

Jahan N, Rehman S, Meda S, Tijani L. Abstract P5-18-14: The relative risk of pneumonitis associated with neoadjuvant chemoimmunotherapy use in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Cancer Res. 2022;82(4_Supplement):18–4.